Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Two COVID shots effective against India variant - English health body

Sat, 22nd May 2021 22:30

LONDON, May 22 (Reuters) - A double dose of COVID-19
vaccines is almost as effective against the fast-spreading
variant of the coronavirus first identified in India as it is
against Britain's dominant strain, English health officials said
on Saturday.

Britain's health minister said the data was groundbreaking
and he was increasingly hopeful that the government would be
able to lift more COVID restrictions next month.

A study by Public Health England found the Pfizer-BioNTech
vaccine was 88% effective against symptomatic disease from the
B.1.617.2 variant two weeks after the second dose.

That compared with 93% effectiveness against the B.1.1.7
"Kent" strain which is Britain's dominant COVID variant.

Two doses of the AstraZeneca vaccine were 60% effective
against symptomatic disease from the Indian variant compared
with 66% effectiveness against the Kent variant, PHE said.

"I'm increasingly confident that we're on track for the
roadmap, because this data shows that the vaccine, after two
doses, works just as effectively (against the Indian variant),"
Health Secretary Matt Hancock told broadcasters.

Under the government's plans, a lifting of remaining
coronavirus restrictions is due to take place from June 21.

Britain has rushed out Europe's fastest vaccination
programme so far but it has faced a new challenge from the
spread of the variant first found in India.

Data published on Saturday showed new COVID cases reported
in Britain rose by 10.5% in the seven days to May 22 although it
remained a fraction of levels seen earlier this year.

Prime Minister Boris Johnson this month ordered an
acceleration of remaining second doses to the over 50s and
people who are clinically vulnerable.

PHE said a first dose of both vaccines was 33% effective
against symptomatic disease from B.1.617.2 after three weeks,
lower than its 50% effectiveness against B.1.1.7.

Hancock said that showed that getting both doses of the
vaccine was "absolutely vital."

Concern about rising cases in Britain of the variant first
found in India prompted Germany to say on Friday that anyone
entering the country from the United Kingdom would have to
quarantine for two weeks on arrival.

Also on Friday, the head of Germany's public health
institute said existing COVID-19 vaccines might be less
effective against the B.1.617.2 variant.
(Writing by William Schomberg; Editing by Christina Fincher)

More News
12 Dec 2023 16:00

London close: Stocks slip as investors digest US inflation

(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.

Read more
12 Dec 2023 12:07

London midday: FTSE still firmer ahead of US inflation print

(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:53

LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI

(Alliance News) - Stock prices in London opened higher on Tuesday, as investors digest the latest UK unemployment data, before turning their eyes to US inflation this afternoon.

Read more
12 Dec 2023 08:37

AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion

(Alliance News) - AstraZeneca PLC confirmed on Tuesday that it will buy Icosavax Inc, boosting its vaccine portfolio with an "innovative" treatment for respiratory viruses.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:16

AstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn

(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy Icosavax - a US-based clinical-stage biopharmaceutical company - for up to $1.1bn.

Read more
12 Dec 2023 02:00

UK companies pause China investment decisions as economy slows, survey shows

BEIJING, Dec 12 (Reuters) - A slowdown in both the Chinese and global economies is the biggest issue affecting British firms in the world's second-largest economy, beating geopolitical concerns and market access barriers, according to the British Chamber of Commerce in China.

Read more
11 Dec 2023 08:15

AstraZeneca says danicopan tests well as blood disorder treatment

(Alliance News) - AstraZeneca PLC on Monday reported "positive results" from a test of danicopan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, a rare and severe blood disorder.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
1 Dec 2023 08:52

LONDON MARKET OPEN: Miners give FTSE 100 boost thanks to China PMI

(Alliance News) - Stock prices in London opened higher on Friday, with the FTSE 100 boosted by mining stocks.

Read more
1 Dec 2023 08:33

AstraZeneca discontinues two phase III evidence trials for Lokelma

(Alliance News) - AstraZeneca on Friday said it has decided to discontinue the Stabilize-CKD and Dialize-outcomes phase III trials for Lokelma, citing increased enrolment timelines.

Read more
1 Dec 2023 08:01

AstraZeneca calls off two phase III trials into hyperkalaemia treatment

(Sharecast News) - Drugmaker AstraZeneca has called off two phase III trials on its hyperkalaemia treatment after a series of logistical challenges.

Read more
1 Dec 2023 07:41

LONDON BRIEFING: Stocks called higher; UK house prices fall annually

(Alliance News) - Stocks in London are called to open higher on Friday, following data from Nationwide showing that the annual pace of UK house price decline slowed in November.

Read more
27 Nov 2023 16:12

London close: Stocks start week in subdued state

(Sharecast News) - London's financial markets saw a somewhat subdued performance on Monday, as concerns regarding the Chinese economy cast a shadow over investor sentiment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.